Expression of leukemia/lymphoma related factor (LRF/Pokemon) in human benign prostate hyperplasia and prostate cancer

被引:29
|
作者
Aggarwal, Himanshu [1 ]
Aggarwal, Anshu [1 ]
Hunter, William J., III [2 ]
Yohannes, Paulos [3 ]
Khan, Ansar U. [3 ]
Agrawal, Devendra K. [1 ]
机构
[1] Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA
[2] Creighton Univ, Med Ctr, Dept Pathol, Omaha, NE 68131 USA
[3] Urol Hlth Ctr, Fremont, NE USA
关键词
Prostate cancer; Pokemon; Benign prostate hyperplasia; LRF; ZBTB7; TRANSCRIPTION FACTOR POKEMON; PROGRESSION; REGULATOR; MEDIATORS; DOMAIN; GENE;
D O I
10.1016/j.yexmp.2011.01.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Leukemia/lymphoma related factor (LRF), also known as Pokemon, is a protein that belongs to the POK family of transcriptional repressors. It has an oncogenic role in many different solid tumors. In this study, the expression of LRF was evaluated in benign prostate hyperplastic (BPH) and prostate cancer (PC) tissues. The functional expression of LRF was studied using multiple cellular and molecular methods including RT-PCR, western blotting, immunohistochemistry, and immunofluorescence. Paraffin-embedded human tissues of BPH and PC were used to examine LRF expression. Histological staining of the BPH and PC tissue sections revealed nuclear expression of LRF with minimal expression in the surrounding stroma. The semi-quantitative RT-PCR and western immunoblot analyses demonstrated significantly higher mRNA transcripts and protein expression in PC than BPH. High expression of LRF suggests that it may have a potential role in the pathogenesis of both BPH and prostate cancer. Further studies will help elucidate the mechanisms and signaling pathways that LRF may follow in the pathogenesis of prostate carcinoma. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:226 / 230
页数:5
相关论文
共 50 条
  • [21] Benign prostatic hyperplasia and prostate cancer
    Guess, HA
    EPIDEMIOLOGIC REVIEWS, 2001, 23 (01) : 152 - 158
  • [22] BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE
    BYAR, DP
    LANCET, 1975, 1 (7911): : 866 - 866
  • [23] Benign prostatic hyperplasia, cancer of the prostate
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (02): : F40 - F42
  • [24] Benign prostatic hyperplasia, prostate cancer
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (03): : F60 - F62
  • [25] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2015, 25 (02): : F58 - F60
  • [26] Benign prostatic hyperplasia, prostate cancer
    Masson-Lecomte, A.
    PROGRES EN UROLOGIE, 2014, 24 (01): : F27 - F30
  • [27] Diagnostic value of SHB expression in human prostate cancer tissue and in benign prostatic hyperplasia
    Schmidt, M.
    Svobodova, E.
    Semanekova, V.
    Klabanova, M.
    Mares, J.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 465 - 466
  • [28] Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer
    Habermann, H
    Ray, V
    Habermann, W
    Prins, GS
    JOURNAL OF UROLOGY, 2001, 166 (06): : 2267 - 2272
  • [29] Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling
    Luo, J
    Duggan, DJ
    Chen, YD
    Sauvageot, J
    Ewing, CM
    Bittner, ML
    Trent, JM
    Isaacs, WB
    CANCER RESEARCH, 2001, 61 (12) : 4683 - 4688
  • [30] Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer
    Choi, Sung-Yup
    Choi, Kyungho
    Jeon, Ju-Hong
    Kim, Chai-Wan
    Shin, Dong-Myung
    Lee, Jong Bouk
    Lee, Sang Eun
    Kim, Choung-Soo
    Park, Jeong-Soo
    Jeong, Eui Man
    Jang, Gi-Yong
    Song, Kye-Yong
    Kim, In-Gyu
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2010, 42 (04): : 310 - 318